Depression Studies

Otsuka - OPC-34712 study
• Diagnosis of Major Depressive Disorder
• Age 18-65
• Evaluating a new drug OPC-34712 that will be added to a patient's antidepressant regimen.
• Patient will be provided with an open-label anti-depressant medication in addition to the study medication throughout the study trial.

Forest – Vilazodone study
• Diagnosed of Major Depressive Disorder
• Age 18-70
• Evaluating the efficacy, safety and tolerability of two fixed dose levels of the already FDA approved medication called Vilazodone (Viibryd) relative to placebo.

Pfizer – PF-05212375 study
• Diagnosed of Major Depressive Disorder
• Age 7-17
• Evaluating desvenlafaxine SR (Pristiq)
• MDD moderate severity with at least one month of symptoms
• Not to have a history of failure to respond to either venlafaxine, desvenlafaxine or fluoxetine
• Other prohibited medications, including antidepressants will need to be washed out.